Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
fatty liver disease
Pharma
Madrigal's MASH drug Rezdiffra 'blew away' expectations in Q3
Madrigal Pharmaceuticals potential blockbuster Rezdiffra racked up sales of $62 million in the third quarter, which routed Wall Street's expectations.
Kevin Dunleavy
Oct 31, 2024 3:24pm
Sales strong for Madrigal's Rezdiffra, but shares down 13%
Aug 7, 2024 2:56pm
With FDA nod for Iqirvo, Ipsen and Genfit will take on Intercept
Jun 11, 2024 11:07am
Lilly pads tirzepatide's MASH win with detailed fibrosis data
Jun 5, 2024 3:04pm
Madrigal builds launch infrastructure for MASH drug Rezdiffra
May 7, 2024 11:56am
Docs sing praises of Madrigal's Rezdiffra, predict rapid uptake
Apr 8, 2024 7:45am
